SILEX SYSTEMS LIMITED — Capital/Financing Update 2025

Sep 2, 2025

==> picture [282 x 72] intentionally omitted <==

==> picture [159 x 72] intentionally omitted <==

==> picture [452 x 28] intentionally omitted <==

Not for release to US wire services or distribution in the United States

Completion of Share Purchase Plan

3 September 2025

Silex Systems Limited ( Silex or the Company ) ( ASX: SLX; OTCQX: SILXY ) is pleased to announce the successful completion of its Share Purchase Plan ( SPP ). The SPP closed on Friday, 29 August 2025 with eligible applications received totalling ~$19.4 million (following final reconciliation and analysis), well in excess of the Company’s target of $15 million. The Company is pleased to advise that it has accepted all valid applications from eligible shareholders under the SPP.

The SPP was announced on 7 August 2025 following the completion of a $130 million placement ( Placement ). The SPP was offered to eligible shareholders with each eligible shareholder allowed to subscribe for up to $30,000 of new ordinary shares in the Company. 4,978,649 new fully paid ordinary shares in the Company ( New Shares ) will be issued pursuant to the SPP at $3.90, being the same as the issue price under the Placement, for total SPP proceeds of ~$19.4 million (before costs).

The New Shares are due to be issued on Friday, 5 September 2025 and are expected to start trading on the ASX on Monday, 8 September 2025.

Following completion of the Placement and SPP, the Company will have a total of approximately 276.7 million shares on issue.

Consistent with the strong interest in the recent Placement from local and international institutional investors, there was also very strong demand for shares offered under the SPP. Proceeds from the Placement and SPP will be to primarily support the commercialisation of the SILEX uranium enrichment technology in the US through exclusive licensee Global Laser Enrichment ( GLE ), and, additionally, to pursue other isotope enrichment opportunities, to fund working capital, and for other general corporate purposes.

Authorised for release by the Silex Board of Directors.

Further information on the Company’s activities can be found on the Silex website: www.silex.com.au or by contacting:

Michael Goldsworthy Julie Russell CEO/Managing Director CFO/Company Secretary T +61 2 9704 8888 T +61 2 9704 8888 E investor.relations@silex.com.au E investor.relations@silex.com.au

Silex Systems Limited | ABN 69 003 372 067 LHSTC, New Illawarra Road, Lucas Heights NSW 2234 Telephone: +61 2 9704 8888 | Facsimile: +61 2 9704 8851 | Website: www.silex.com.au

==> picture [159 x 72] intentionally omitted <==

Important Information:

About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY)

Silex Systems Limited ABN 69 003 372 067 ( Silex or Company ) is a technology commercialisation company, the primary asset of which is the SILEX laser enrichment technology ( SILEX technology ), originally developed at the Company’s technology facility in Sydney, Australia. The SILEX technology has been under development for uranium enrichment jointly with US-based exclusive licensee, Global Laser Enrichment LLC ( GLE ), for a number of years. Success of the SILEX uranium enrichment technology development program and the proposed Paducah commercial project remain subject to a number of factors, including the satisfactory completion of the TRL-6 pilot demonstration program, nuclear fuel market conditions, industry and government support, project feasibility, and commercial plant licensing, and, therefore, remains subject to associated risks.

Silex also is at various stages of development of additional commercial applications of the SILEX technology, including the production of ‘Quantum Silicon’ ( Q-Si ) for the emerging technology of silicon-based quantum computing. The Q-Si Project remains dependent on the outcomes of the Project, as well as the successful development of silicon-based quantum computing technology by third parties, and is, therefore, subject to various risks. Silex also is conducting earlystage research activities in its Medical Isotope Separation Technology ( MIST ) Project, which also is subject to various risks and outcomes. The commercial future of the SILEX technology in application to uranium, silicon, medical, and other isotopes therefore is uncertain, and any plans for commercial deployment are speculative.

Forward Looking Statements

The commercial potential of the abovementioned technologies and activities is currently unknown. Accordingly, no guarantees as to the future performance of these technologies can be made. The nature of the statements in this Announcement regarding the future of the SILEX technology as applied to uranium enrichment, Q-Si production, medical and other isotope separation projects, and any associated commercial prospects, including TRL-6 achievement and other commercialisation milestones at GLE, are forward-looking and are subject to a number of variables, including, but not limited to, known and unknown risks, contingencies, and assumptions that may be beyond the control of Silex, its directors, and management. You should not place reliance on any forward-looking statements as actual results could be materially different from those expressed or implied by such forward-looking statements, as a result of various risk factors. Further, the forward-looking statements contained in this disclosure involve subjective judgement and analysis and, accordingly, are subject to: change at any time due to variations in the outlook for, and management of, Silex’s business activities (including project outcomes); changes in industry trends and government policies; and new or unforeseen circumstances. The Company’s management believes that there are reasonable grounds to make such statements as at the date of this disclosure. Silex does not intend, and is not obligated, to update the forward-looking statements except to the extent required by law or the ASX Listing Rules. None of Silex, its related companies, or any of their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents, or advisers makes any representation or warranty as to the accuracy of any forward-looking statements contained in this Announcement.

Not Advice

Information in this Announcement, including forecast financial information, should not be considered as investment, legal, tax, or other advice. You should make your own assessment and seek independent professional advice in connection with any investment decision.

Risk Factors

Risk factors that could affect the future results and commercial prospects of Silex include, but are not limited to: ongoing economic and social uncertainty, including in relation to global economic stresses, such as interest rates; inflation; tariffs (including tariffs imposed by the United States); geopolitical risks, in particular, those relating to Russia’s invasion of Ukraine and tensions between China and Taiwan, which may affect global supply chains and capital markets; uncertainties related to the effects of climate change and mitigation efforts; the results of the GLE/SILEX uranium enrichment pilot demonstration ( TRL-6 ) program; the market demand for natural uranium and enriched uranium; the outcome of the Q-Si Project for the production of enriched silicon for the emerging silicon-based quantum computing industry; the outcome of the MIST Project; the potential development of, or competition from, alternative technologies; the regulatory changes and evolving eligibility criteria under the US Inflation Reduction Act (2022) and the Nuclear Fuel Security Act (2023) the potential for third party claims against the Company’s ownership of Intellectual Property; the potential impact of prevailing laws or government regulations or policies in the US, Australia, or elsewhere; actions taken by the Company’s commercialisation partners and other stakeholders that could adversely affect the technology development programs and commercialisation strategies of Silex; and the outcomes of various strategies and projects undertaken by the Company.

Page 2 of 2